RT Journal Article
SR Electronic
T1 Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 396
OP 398
DO 10.2967/jnumed.121.262344
VO 63
IS 3
A1 Justin Ferdinandus
A1 Wolfgang P. Fendler
A1 Katharina Lueckerath
A1 Christoph Berliner
A1 Sabine Kurzidem
A1 Eva Hadaschik
A1 Joachim Klode
A1 Lisa Zimmer
A1 Elisabeth Livingstone
A1 Dirk Schadendorf
A1 Ken Herrmann
A1 Juergen C. Becker
A1 Selma Ugurel
YR 2022
UL http://jnm.snmjournals.org/content/63/3/396.abstract
AB For patients with Merkel cell carcinoma (MCC) who are refractory to immune checkpoint inhibition (ICI), treatment options are limited. Few cases of MCCs have been reported to show responses to peptide receptor radionuclide therapy (PRRT). A combination of PRRT and ICI has not been reported in MCC to date. A patient with metastatic MCC, who was resistant to first-line avelumab and acquired resistance to ipilimumab/nivolumab (IPI/NIVO) with additional radiotherapy, presented with multiple distant metastases. After confirmation of SSTR expression, treatment was continued with an additional 4 doses of IPI/NIVO combined with 2 cycles of PRRT. Treatment was well tolerated, with transient hemotoxicity and mild nausea. Restaging after 3 mo demonstrated an exceptional response. This case demonstrates the feasibility of combined treatment with IPI/NIVO and PRRT as an option for MCC patients progressing under ICI. Prospective evidence confirming the additive value of combining ICI and radionuclide therapy in a larger cohort is needed.